On April 15, 2020 Hansa Biopharma reported that it will publish its interim report for January-March 2020 at 8:00 a.m. CET on April 28, 2020 (Press release, Hansa Biopharma, APR 15, 2020, https://www.prnewswire.com/news-releases/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-quarter-of-2020-and-business-update-301040783.html [SID1234556364]). All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call.

On April 15, 2020 Cardinal Health (NYSE: CAH) reported plan to release third-quarter financial results for its fiscal year 2020 on May 11 prior to the opening of trading on the New York Stock Exchange (Press release, Cardinal Health, APR 15, 2020, View Source [SID1234556363]). The company will webcast a discussion of these results and its outlook for the remainder of its fiscal year 2020 beginning at 8:30 a.m. Eastern.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. Presentation slides and a webcast replay will be available until May 10, 2021.

On April 15, 2020 ArcherDX, Inc., reported that new data from its research collaboration with UCL and the Francis Crick Institute as part of the Cancer Research UK-funded UCL-sponsored TRACERx study was chosen to be presented by UCL on Tuesday, April 28 at 2:15 p.m. ET during the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting (Press release, ArcherDX, APR 15, 2020, View Source [SID1234556362]). The TRACERx study, a translational research program taking place over nine years, follows patients with lung cancer from diagnosis to either disease relapse or cure after surgery, tracking and analyzing how their cancer develops.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Clinicians are eager to expand precision oncology into early-stage cancer, when the cancer is typically easier to cure compared to late-stage cancer. Current monitoring methods, such as diagnostic imaging and cancer antigen tests, lack resolution and accuracy needed to monitor early-stage disease. Our technology allows for clinicians to use the assays in local labs and maintain control of the data," said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX. "This collaboration with UCL and the Francis Crick Institute aims to detect minimal residual disease, earlier by tracking personalized, patient-specific mutations."

As part of an ongoing collaboration, TRACERx1 investigators, led by Professor Charles Swanton, Group Leader, UCL and the Francis Crick Institute, and Dr. Christopher Abbosh, Principal Clinical Fellow, UCL, are utilizing ArcherDX’s technology to detect low-volume minimal residual disease at high levels of sensitivity to achieve TRACERx’s goal of a more personalized approach to developing cancer treatments.

Oral Presentation Details
The virtual meeting is free and available to anyone by registering at aacr.org.

Presentation Title:

Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study

Presenter:

Christopher Abbosh, M.D., Principal Clinical Fellow, University College London

Session Title:

Early Detection and ctDNA

Session Date and Time:

Tuesday, April 28 at 2:15 p.m. ET

Abstract Number:

2025

On April 15, 2020 PIC Therapeutics ("PIC"), a biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, reported that it closed a $5M Series Seed round of preferred equity funding (Press release, PIC Therapeutics, APR 15, 2020, View Source [SID1234556361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oversubscribed round was led by Advent Life Sciences ("Advent"), and included participation by Belinda Termeer, widow of legendary Genzyme CEO Henri Termeer, as well as several biopharmaceutical industry executives and other individual investors.

PIC Therapeutics was founded based on the extensive research of scientific founder Professor Gerhard Wagner of Harvard University and is led by founding CEO Sun Altbach, a 20+ year life sciences veteran and by Dr. Alan Walts, Executive Chairman and Venture Partner at Advent Life Sciences. PIC is supported by a world-renowned Scientific Advisory Board and Board of Directors.

PIC targets the "master switch" of cancer signaling pathways, blocking oncogene protein production by selectively modulating the Pre-Initiation Complex (PIC), specifically eIF4E – a convergence point driving oncogene RNA translation. PIC Therapeutics’ targeted approach has the potential to simultaneously impact multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics that address drug resistance and tumor heterogeneity, issues that plague many existing treatments.

Sun Altbach, CEO commented, "This is an important step for PIC as we seek to transform how cancer is treated and therefore make a significant difference in patients’ lives. With this funding in hand we can accelerate our program focusing on allosteric regulation of eIF4E via an innovative drug development platform designed to produce early proof of concept in advance of the clinic."

Alan Walts, Executive Chairman and Venture Partner at Advent added, "PIC is a leader in the rapidly advancing field of translational modulation of oncogenes. PIC has developed a best in class portfolio of proprietary small molecule modulators of eIF4E and a comprehensive platform to validate human tumor activity. We are pleased to support their efforts to develop a new class of cancer therapies."

PIC’s Board of Directors consists of:

Alan Walts, PhD, Executive Chairman of the Board; Venture Partner, Advent Life Sciences
Sun Altbach, MBA, CEO and President, PIC Therapeutics
Richard Peters, MD, PhD, Co-Founder, PIC Therapeutics; CEO Yumanity Therapeutics
Belinda Termeer, Termeer Foundation
Gerhard Wagner, PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
PIC’s Scientific and Corporate Advisory Board consists of:

Keith Flaherty, MD, Director of Clinical Research at the Cancer Center at MGH
Jennifer Petter, PhD, Founder and Chief Scientific Officer of Arrakis Therapeutics
Nahum Sonenberg, PhD, Biochemistry Professor and Gilman Cheney Chair, McGill University
Yat Sun Or, PhD, Chief Scientific Officer, Enanta Pharmaceuticals
Jan Van Heek, MBA, Board Member, Amarin Corporation and Minerva Neuroscience
Gerhard Wagner, PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

On April 15, 2020 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported launch of its novel therascreen BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration (FDA) approval as a companion diagnostic to the BRAF inhibitor, BRAFTOVI (encorafenib), which the FDA has approved for use in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy (Press release, Qiagen, APR 15, 2020, View Source [SID1234556360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Colorectal cancer is the third most common type of cancer, and approximately 150,000 patients a year in the United States are diagnosed with CRC. In primary and metastatic CRC, BRAF mutations (nearly always V600E) are present in up to 15% of patients and are thought to be key drivers of tumor growth. Detection of the V600E mutation utilizing the therascreen BRAF V600E assays will help identify patients eligible for treatment with the newly approved combination of BRAFTOVI and cetuximab. The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx, a member of the modular QIAsymphony family of automation solutions.

"We are very excited about the launch of the new therascreen BRAF V600E Kit, our first companion diagnostic test to obtain FDA approval for the detection of a mutation in the BRAF gene and our third CDx approval in colorectal cancer. Using our new test to help guide treatment decisions in colorectal cancer will address a high unmet medical need among patients," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. "The new therascreen BRAF V600E Kit will be available to accelerate the availability of innovations in precision medicine."